Weight Often Returns After Stopping GLP-1 Weight-Loss Drugs, Raising Concerns About a New Yo-Yo Effect

A new generation of weight-loss medications, including Wegovy and Mounjaro, has transformed the treatment of obesity. However, growing evidence suggests that many patients regain a significant portion of the weight they lose after discontinuing these medications, according to The Conversation.

These drugs belong to the GLP-1 receptor agonist class. They mimic hormones released after eating, helping people feel full sooner and reducing appetite. Mounjaro (tirzepatide) also targets a second hormone involved in blood sugar regulation and appetite control, making it particularly effective for weight management.

With more than one billion people worldwide living with obesity, these medications have been hailed as a major breakthrough. However, researchers are increasingly focusing on an important question: what happens after treatment ends?

Studies show that many patients regain a substantial amount of the weight they lost after stopping GLP-1 therapy. This weight regain may also be accompanied by a worsening of certain health indicators, including cardiovascular risk factors.

Researchers believe this occurs because the medications directly suppress appetite. During treatment, many patients experience a reduction in what is often called "food noise"—persistent thoughts about food, cravings, and feelings of hunger. Once the medication is discontinued, this effect gradually fades, appetite returns, and maintaining previous eating habits becomes much more difficult.

These findings have raised concerns about a new form of the "yo-yo effect," in which patients lose weight, regain it after stopping treatment, and eventually require another course of medication.

Experts stress that the issue does not lie with the medications themselves. GLP-1 drugs have consistently demonstrated their effectiveness and can substantially improve the health of people living with obesity. However, obesity is increasingly recognized as a chronic disease influenced not only by diet and willpower but also by biology, lifestyle, stress, sleep, access to healthy food, and social factors.

According to physicians, GLP-1 medications should be viewed as tools that create favorable conditions for lasting lifestyle changes rather than as a standalone solution. By reducing appetite, they can make it easier for patients to establish healthier eating habits, increase physical activity, and develop strategies to manage situations that trigger overeating.

The growing use of these medications also raises new challenges for healthcare systems. Some patients may require long-term treatment, particularly those with severe obesity or obesity-related diseases. Others may need repeated courses of therapy because of medication costs, limited access, or personal circumstances.

Follow NEWS.am Medicine on Facebook and Twitter